These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma. Harshman LC; Barbeau S; McMillian A; Srinivas S Clin Genitourin Cancer; 2013 Jun; 11(2):100-6. PubMed ID: 23352238 [TBL] [Abstract][Full Text] [Related]
25. Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell cancer. Amato RJ; Mohammad T J Exp Ther Oncol; 2008; 7(1):41-7. PubMed ID: 18472641 [TBL] [Abstract][Full Text] [Related]
26. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma. de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308 [TBL] [Abstract][Full Text] [Related]
27. Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan. Eto M; Kawano Y; Hirao Y; Mita K; Arai Y; Tsukamoto T; Hashine K; Matsubara A; Fujioka T; Kimura G; Shinohara N; Tatsugami K; Hinotsu S; Naito S; BMC Cancer; 2015 Oct; 15():667. PubMed ID: 26452347 [TBL] [Abstract][Full Text] [Related]
28. Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890). Dutcher JP; Fine JP; Krigel RL; Murphy BA; Schaefer PL; Ernstoff MS; Loehrer PJ Med Oncol; 2003; 20(3):271-81. PubMed ID: 14514977 [TBL] [Abstract][Full Text] [Related]
29. Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma. Nathan PD; Gore ME; Eisen TG J Clin Oncol; 2002 Mar; 20(5):1429-30. PubMed ID: 11870194 [No Abstract] [Full Text] [Related]
33. Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines. Poprach A; Pavlik T; Melichar B; Kubackova K; Bortlicek Z; Svoboda M; Lakomy R; Vyzula R; Kiss I; Dusek L; Buchler T; Urol Oncol; 2014 May; 32(4):488-95. PubMed ID: 24321257 [TBL] [Abstract][Full Text] [Related]
34. Multicenter phase II trial of combination therapy with meloxicam, a cox-2 inhibitor, and natural interferon-alpha for metastatic renal cell carcinoma. Shinohara N; Kumagai A; Kanagawa K; Maruyama S; Abe T; Sazawa A; Nonomura K Jpn J Clin Oncol; 2009 Nov; 39(11):720-6. PubMed ID: 19684042 [TBL] [Abstract][Full Text] [Related]
35. Fulminant type 1 diabetes caused by dual immune checkpoint blockade in metastatic renal cell carcinoma. Teló GH; Carvalhal GF; Cauduro CGS; Webber VS; Barrios CH; Fay AP Ann Oncol; 2017 Jan; 28(1):191-192. PubMed ID: 28043983 [No Abstract] [Full Text] [Related]
36. A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations. Bex A; Albiges L; Staehler M; Bensalah K; Giles RH; Dabestani S; Hofmann F; Hora M; Kuczyk MA; Lam TB; Marconi L; Merseburger AS; Fernández-Pello S; Tahbaz R; Abu-Ghanem Y; Volpe A; Ljungberg B; Escudier B; Powles T Eur Urol; 2018 Dec; 74(6):849-851. PubMed ID: 30201510 [No Abstract] [Full Text] [Related]
37. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors. Busch J; Seidel C; Kempkensteffen C; Johannsen M; Wolff I; Hinz S; Magheli A; Miller K; Grünwald V; Weikert S Eur Urol; 2011 Dec; 60(6):1163-70. PubMed ID: 21802830 [TBL] [Abstract][Full Text] [Related]